Oncode Scientific Sdn Bhd
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Oncode Scientific Sdn Bhd - overview
Established
2015
Location
Selangor, -, Malaysia
Primary Industry
Biotechnology
About
Oncode Scientific Sdn Bhd, based in Malaysia, is a biotechnology firm specializing in precision medicine through advanced molecular testing solutions, particularly focusing on oncology and personalized cancer care. Founded in 2015 and headquartered in Selangor, Malaysia, Oncode Scientific Sdn Bhd specializes in molecular testing for cancer diagnosis. The company has conducted one significant deal as of August 13, 2025, reflecting its operational growth and engagement in the biotechnology sector. Oncode Scientific specializes in precision medicine, offering advanced molecular testing solutions for oncology.
Their core product offerings include comprehensive tissue biopsy testing and liquid biopsy services that utilize technologies such as Next Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), and fragment analysis. These services encompass a wide variety of genetic markers, including single nucleotide variants (SNVs) and copy number variations (CNV), aimed at empowering healthcare professionals with actionable insights for personalized cancer treatment. Their clientele primarily consists of healthcare professionals, oncologists, and research institutions, both in Southeast Asia and globally, reinforcing their commitment to enhancing patient care through tailored therapeutic strategies. Oncode Scientific operates a B2B business model, primarily serving healthcare providers and institutions.
Their revenue is generated through specialized molecular testing services accessed via partnerships with hospitals and clinics. Clients engage Oncode for services such as tissue biopsies and liquid biopsies, with testing arrangements that include one-time fees per test conducted. The company boasts established relationships with over 150 healthcare partners, reflecting high customer satisfaction and consistent demand for advanced diagnostic capabilities in oncology. In August 2025, Oncode Scientific Sdn Bhd raised an undisclosed amount of venture funding from Malaysian Technology Development.
This funding will support the development of new molecular testing products and facilitate expansion into Southeast Asian markets. The company aims to enhance its offerings further and reach additional healthcare institutions by leveraging innovative technologies and strategic partnerships.
Current Investors
Malaysian Technology Development
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Oncology/Cancer Treatment
Website
www.oncodesc.com
Company Stage
Early Stage
Total Amount Raised
Subscriber access only
Oncode Scientific Sdn Bhd - financials
| Fiscal Year Ended | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 92,150 | 54,350 | 712,889 | 1,814,396 | 3,741,666 | - | - | - |
| % Revenue Growth (YoY) | - | (41.0%) | 1211.7% | 154.5% | 106.2% | - | - | - |
| EBITDA (USD) | (197,479) | (997,038) | (879,354) | (365,483) | 743,674 | - | - | - |
| Operating Income (USD) | (212,560) | (1,162,242) | (1,047,111) | (534,075) | 540,255 | - | - | - |
| Operating Margin | (230.7%) | (2138.4%) | (146.9%) | (29.4%) | 14.4% | - | - | - |
| % EBITDA Margin | (214.3%) | (1834.5%) | (123.4%) | (20.1%) | 19.9% | - | - | - |
| NET Income (USD) | (212,253) | (1,254,159) | (1,378,611) | (833,499) | 288,249 | - | - | - |
| % Net Margin | (230.3%) | (2307.6%) | (193.4%) | (45.9%) | 7.7% | - | - | - |
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.